This problem that plagues cancer patients is welcome to welcome new therapy!Ping An Yanye new medicine naldemedine film landing Music City

Author:Hainan Boao Le City Pioneer Ar Time:2022.09.26

Recently, the NALDEMEDIDINE film (product name: SymProic® tablets) of Ping An Yanye Yiyi Co., Ltd. (hereinafter referred to as "Ping An Yanye Yiyi") was approved in Hainan Boao Leo City International Medical Tourism Zone ("Lecheng Pioneer District") Putting on the ground is used to treat patients with opioids (referred to as "OIC") in patients with cancer.

NALDEMEDINE tablets are peripheral μ-opioid receptor antagonists (PAMORAS [1]) developed by Yanye Pharmaceutical Co., Ltd., which are currently in the United States (2017), EU (2019), Japan (2017) and Taiwan, China Regional (2021) was approved to be listed, and the approved indications in Japan and Taiwan were constipation caused by opioid drugs.

NALDEMEDINE tablets are an innovative new drug developed by the Yanye Pharmaceutical Co., Ltd. It has been recommended by multiple authoritative guidelines around the world as a standard scheme for treating opioids. Ping An Yanye Yiyi is conducting clinical trials in China, which aims to be approved in China as soon as possible to provide new treatment plans for relevant Chinese patients. Before the official listing, we were glad to see the NalDemedine film approved to be approved to land in Music City, and OIC patients were able to obtain this innovative medicine as soon as possible. Ping An Yanye will also be firmly committed to supporting China's cancer and priority treatment in the future, so that cancer patients can share a happy life with their families.

Ping An Yanye Yiyi Co., Ltd.

Deputy General Manager of New Medicine Development Department

Mizuno Bodao

Regarding the constipation caused by opioid drugs (OIC)

And the existing situation in China

Oed drugs are commonly used clinical analgesic drugs. The World Health Organization advocates treating it as a recommended treatment for cancer pain [2]. As the number of cancer patients increases, the number of prescriptions for opioid drugs will increase accordingly. However, the results of clinical practice show that long -term use of opioids can lead to various adverse reactions, which is quite common and significant in constipation (OIC) caused by opioid drugs. After the opioid drugs combine and activate the μ opioid receptor distributed in the small intestine and the proximal colon in the peripheral nervous system, the intestinal movement becomes slow, the intestinal liquid secretion decreases, and the end of the intestine is increased. This increases. This increases. This increases. The superposition of the series effect causes constipation. According to a review of Nabil Almouaalamy, the incidence range of OIC in advanced cancer patients treated with opioid drugs is 51%to 87%[3]. Jay Thomas summarizes in its article that the symptoms of OIC can significantly interfere with patients' daily life activities, leading to a reduction in quality of life, and it usually does not relieve it with time. [4]

Currently in China, OIC patients can only obtain some limited treatment countermeasures, such as: symptomatic treatment drugs (such as various traditional laxatives), physical measures (such as enema, etc.), Chinese medicine, Chinese medicine treatment (such as acupuncture or massage, etc.), or Change the dose or type of opioid drugs. If these measures do not have a good effect, the patient's pain management will be greatly affected, and the quality of life will decrease sharply. Therefore, in China, patients with light laxatives are urgently needed for new treatment plans.

About naldemedine films

(Commodity name: Symproic® film)

NALDEMEDINE tablets are an antagonist developed by the μ-opioid receptor of the outer peripheral nervous system μ-opioid receptor, referred to as PAMORAS [1]. It can regulate intestinal peristalsis and secretion activity in the intestinal nervous system in the peripheral tissue (especially the intestinal nervous system) to regulate the intestinal peristalsis and secretion activities, and fundamentally treat the constipation of patients with OIC. Naldemedine tablets started with the treatment of OIC. By improving the analgesic experience of cancer patients using opioid drugs, the quality of life of cancer patients was ultimately improved.

Based on the "patient -centered" drug research and development concept, Ping An Yanye Yiyi introduced NalDemedine tablets from the Yanye Pharmaceutical Co., Ltd. to provide OIC treatment plan for cancer patients who were treated with palliative treatment. This product has also been introduced as a clinical need for drugs to introduce the pioneer area for clinical urgently needed drugs to participate in the free use of OIC patients in the clinical observation project initiated by Professor Wang Lin initiated by Professor Wang Lin initiated by Hainan Provincial People's Hospital. Cancer with demand meters of OIC can visit the specialist clinic of Director Wang Lin, Dr. Wang Haixia and Dr. Shengli in Hainan Provincial People's Hospital to explore the feasibility of participating in the clinical observation project.

About Ping An Yan Yeyi

Ping An Yanye Yiyi Co., Ltd. is a joint venture jointly invested by China Ping An Group and Japan's Yanye Yisi Pharmaceutical Co., Ltd., headquartered in Shanghai. One of its parent companies, the Yanyan Yisi Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company established in 1878. It has a history of more than 140 years, has a strong new drug research and development capabilities. Deep technical accumulation.

As the product of the two companies, Ping An Yan Yeyi Co., Ltd. is committed to establishing a comprehensive medical platform to meet the various medical needs of the Chinese people through new drug research and development, Internet medical care.